Carle Cancer Institute is the premier cancer treatment and support center in east central Illinois, offering more resources to help patients in the fight against cancer. With the area's largest and most specialized team of fellowship trained oncologists, surgeons and staff, patients get in for diagnosis and start treatment as soon as possible. Our team offers the latest technology and highly specialized multidisciplinary clinics for certain cancers, including breast, prostate, gynecologic, and head and neck. But we don't just treat a disease – we care for the whole patient, offering support groups, genetic and nutrition counseling, nurse navigator services and more.
Our experts in oncology, breast imaging, reconstructive surgery, genetics, research and support services, give you the tools you need in the fight against breast cancer.
With a team approach to care, experts at Carle Cancer Institute develop an individualized plan of treatment for patients with gastrointestinal cancer.
Carle gynecologic oncology team serves women who have or are suspected of having ovarian, cervical, endometrial, and vulvar cancers.
The Carle Cancer Institute focuses on aggressive and effective treatment, helping to instill hope in patients undergoing what is often an unknown journey.
With a team approach to care, experts at Carle Cancer Institute develop an individualized plan of treatment for patients with lung cancer.
With a team approach to care, experts at Carle Cancer Center develop an individualized plan of treatment for patients with lymphoma and leukemia.
Experts at Carle Cancer Institute along with Dermatology and Plastic Surgery experts develop and individualized plan for patients with skin cancer.
Our urologic cancer practice is based on a multi-specialty approach that combines clinical expertise from urology and radiation oncology.
Have a patient referral? Refer a patient now.
Involved in national research for more than 30 years, Carle Cancer Institute offers its patients access to innovative ways to fight cancer through clinical trials. Clinical trials offer new insight into how to combat a disease like cancer and demonstrate new ways of preventing, treating, or possibly curing cancer.
Carle Cancer Institute provides access to clinical trials for several types of cancer including but not limited to breast, lung, colon, melanoma, prostate, and ovarian cancer. We are also actively involved in national prevention clinical trials per cancer type. In addition, we offer symptom management program to address the quality of life of cancer patients.
Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion. --Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die. --The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.
Infigratinib is an oral medication which selectively binds to fibroblast grown factor receptor (FGFR)-2 and is being developed to treat participants with FGFR-2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral Infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR-2 gene fusions/translocations.
This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an ESR1 mutation.---- The secondary objectives are to evaluate:-- 1.Clinical benefit rate (CBR) and Objective Response Rate (ORR)-- 2.Duration of response-- 3.Time to response-- 4.Overall Survival (OS)-- 5.Pharmacokinetics of lasofoxifene-- 6.Quality of life (QoL)-- 7.Safety of lasofoxifene-- 8.Response to various ESR1 mutation subtypes-- 9.The presence of the following mutations from tumor free DNA will be documented and part of an exploratory analysis:-- a.) erbb2 extracellular domain mutation 5310;-- b.) erbb2 kinase domain mutations V777, L755, and Exon 20 insertion;-- 3.all NF1 mutations that are truncating, frame shifting and nonsense or homozygous deletions; and-- 4.KRAS.
With doctors practicing in 80 specialties at locations throughout the region, it’s easy to find the right healthcare team at Carle. Our mission is to serve people through high quality care, medical research and education.
Charitable gifts are used for numerous projects and programs that enhance the healthcare experience for cancer patients and their loved ones. With your support, we’ll continue to work to eliminate cancer through excellence in diagnosis, treatment, research and education.
Recognized among the nation’s top hospitals, Carle provides excellent healthcare while continuously improving to meet the needs of our patients.